CTNow: A Clinical Trials Education Program for Rural Cancer Patients and Oncology Providers

NCT ID: NCT06237816

Last Updated: 2025-11-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

35 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-05-01

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overall goal of the project is to pilot test CTNow, a multilevel intervention designed to facilitate access and referrals to cancer clinical trials in rural areas through patient and provider education and teleconference resources.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer Oncology

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient Education Intervention

A multimedia educational series is designed to provide patient education on cancer clinical trials.

The following topics are addressed:

* What is a clinical trial?
* Types of clinical trials.
* Phases of clinical trials.
* Benefits and drawbacks.
* Costs.
* FAQs. This section covers common myths and clarifies these myths using a Q\&A format.
* How to join a clinical trial. Information about eligibility and informed consent.
* Clinical trial stories. Testimonies from oncology providers and patients. Each module is approximately 2-5 minutes, and they can be reviewed in the order/schedule preferred by the patient.

The overall program is 30 minutes to view including the videos. The tablet provided to patients provides additional benefits for participation.

Group Type EXPERIMENTAL

Patient Education Intervention

Intervention Type OTHER

Multimedia Educational Videos

Provider Education Intervention

The provider education intervention will consist of 3 provider informational sessions conducted individually. These individual provider sessions will be conducted by teleconference by the research team and scheduled according to provider's availability.

Provider workshops are designed to provide both a background on clinical trial infrastructure in Hawaii and resources for additional information. The content of these sessions includes:

* An overview of clinical trials infrastructure in Hawaii.
* Available trials in Hawaii. At each informational session, the research team will review available trials and any new/upcoming trials with the provider.
* An overview of how to get involved in clinical trials. As experience and background re: clinical trials may vary across providers, the content of these informational sessions will be tailored to each provider. Following the initial session, 2 additional meetings will be scheduled in 4-6 months as follow-up sessions.

Group Type EXPERIMENTAL

Provider Education Intervention

Intervention Type OTHER

Provider workshops via zoom

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Patient Education Intervention

Multimedia Educational Videos

Intervention Type OTHER

Provider Education Intervention

Provider workshops via zoom

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must have been diagnosed with any cancer.
* Patients who have received treatment, are receiving cancer treatment at the time of enrollment, or estimated to start treatment within 90 days.
* Patients must be ≥ 18 years of age. Patients must be able to read, write, and speak English. Study materials and telephone calls are only available in English.

Patients must be residents of Hawaii, Kauai, or Maui counties.

Exclusion Criteria

* Patients must not have previously participated in a cancer clinical trial. Those who have participated in a cancer clinical trial are not eligible for the study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Agency for Healthcare Research and Quality (AHRQ)

FED

Sponsor Role collaborator

University of Hawaii

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Izumi Okado, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Hawaii Cancer Research Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Univesity of Hawaii Cancer Center

Honolulu, Hawaii, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Izumi Okado, PhD

Role: CONTACT

Phone: (808) 564-5978

Email: [email protected]

Aaron Roberts

Role: CONTACT

Phone: 8084404583

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Aaron Roberts

Role: primary

Tomomi Otaki

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Okado-2023-2

Identifier Type: -

Identifier Source: org_study_id